On June 5, 2026, the U.S. Department of Justice, acting in coordination with the Ohio Attorney General, announced a resolution with the Cleveland Clinic Foundation that imposes a decades-long commitment by the Clinic to cease offering puberty blockers, cross-sex hormones, and related procedures for minors. The settlement also requires the Clinic to establish a $2 million restorative care fund and to pay a $308,000 penalty to resolve allegations of false diagnosis coding submitted to Ohio Medicaid. As is typical of such resolutions, the Clinic does not admit liability.
While the financial components of the settlement are comparatively modest, the structural relief is significant. The Clinic's agreement to forgo an entire category of clinical services for an extended period reflects a notable departure from traditional False Claims Act resolutions, which generally focus on monetary recoupment and compliance monitoring rather than long-duration restrictions on clinical practice. The use of Medicaid billing and diagnosis coding theories as the predicate for substantive operational restrictions is a development that healthcare providers should examine closely.
The matter also illustrates an emerging federal-state enforcement model in which the DOJ and state attorneys general jointly leverage Medicaid integrity authorities to address conduct that extends well beyond billing irregularities. By aligning federal and state interests, regulators can pursue parallel theories of recovery and secure broader injunctive terms than either sovereign might obtain independently. Hospitals, academic medical centers, and pediatric providers should anticipate that similar coordinated investigations may follow, particularly in jurisdictions where state policy positions on pediatric gender-related care diverge from prior clinical practice.
Providers participating in Medicaid programs should reassess their compliance protocols in light of this resolution. Areas warranting particular attention include the accuracy and specificity of diagnosis coding, internal documentation supporting medical necessity determinations, the alignment of clinical practice with applicable state law, and the scope of representations made in Medicaid claims submissions. Boards and compliance committees should also evaluate enterprise risk associated with service lines that may attract heightened regulatory scrutiny, and consider whether existing internal review structures are sufficient to identify exposure before it ripens into an enforcement matter.
This alert is provided for general informational purposes only and does not constitute legal advice. Clients facing related compliance questions or enforcement inquiries should seek tailored counsel addressing their specific circumstances.